Cell Signalling IV

Descripción

Fichas sobre Cell Signalling IV, creado por J yadonknow el 31/03/2018.
J yadonknow
Fichas por J yadonknow, actualizado hace más de 1 año
J yadonknow
Creado por J yadonknow hace más de 6 años
0
0

Resumen del Recurso

Pregunta Respuesta
Enzyme linked receptors Tyrosine Kinase Receptors (TKRs)
TKRs 1. EXC domain binds ligand. 2. Transmembrane domain 3. IC domain, has TK 4. +Pi Tyr residues from ATP
PK casses TK serine/threonine kinases e.g. PKA/B/C
Binding to PK 1. Ligand binds to monomer 2. Induces conf. Δ in EC dom., dimerise 3. Induces conf. Δ in IC domain. 4. Auto-Pi,reveals substrate BS on opposite R 5. Transphosphorylation. 6. +Pi-Tyr provides docking site for signalling molecule.
GF R signalling +Pi -> Grb2 -> SOS -> Ras GTP
Insulin R signalling 1. Unusual as adaptors are +Pi by receptor themselves. 2. +Pi on IRS provide docking sites for a multitude of signalling cascades. 3. Compensatory mechanism as Insulin R doesn't have many Tyr in IC domain. (extension cord).
Ras Monomeric G protein (acts like alpha SU) + When bound to GTP Intrinsic GTPase activity to - Accessory proteins required to cycle between +/-
+/- of Ras GEFs -> + GAP -> - (Cycle)
Ras signal cascade Ras Y-Pi -> Grb2 -> SOS -> Ras-GDP -> Ras-GTP -> MEK _MAPK -> +Pi-TF Ras-GDP -> Ras-GTP (SOS) Ras-GTP -> Ras-GDP (GAP)
Insulin Receptor Only TK to not dimerise Heterotetrameter in PCM Alpha SU bind to insulin Induces conf. Δ in TK -> trans/auto+Pi
Insulin R cascade Insulin -> Alpha -> trans/auto-> IRS-1 -> PIP2 -> PIP3 -> PDK1 -> PKB -> Glut-4 vesicle translocation
Why do this? Regulates glucose uptake Vesicle translocates to PCM, fuses, takes up glucose, passes it back into cell.
Enzyme -linked R Recruit EZ from cytoplasm e.g. Cytokine R recruit JAK to help initiate cell signalling
MOA (6) 1. Cytokine R lacks intrinsic K activity. 2. Recruit soluble TK i.e. JAK. 3. Ligand binding causes R dimerisation + JAK+ 4. JAK + each other and R 5. Adaptor proteins recruited to +Pi-Tyr on R OR 6. STAT TF directly to JAK
Preferable drug design Small molecules favoured
The protein domains capable of strong+specific interactions w/ drug Has cavity e.g. well defined catalytic cleft
Good/Bad targets? Good: R/EZ Bad: TF (apart from Nuclear R's).
Common target Competitive binding to ATP binding region to prevent gamma-phosphorylation
Nuclear Receptors Ligand + TF
Domain Structure: Mod. conserved ligand-binding dom. Highly conserved DNA binding dom. Highly variable N-term w/ 1(>) + Domains
Categorisation 1 based on MOA and distribution in cell when L absent (5) Category 1: Steroid/androgen R. Found in cyto associated w heat shock protein Forms a homodimer Once in nucleus recruits co-+'s to mod. chromatin/DNA Pol' activity.
Category 2 In nucleus Sit on response cell event (DNA) Form heterodimer, always complexed to RxR Core repressor keeps chromatin compact, preventing gene transcription.
Category 2 diagram Yoooohohoho
Anti-hormone drugs e.g. Tamoxifen Struct similar to hormone, binds to LBD Allows R dimerisation + binding to DNA/gene promoter Side chains rpevent correct structural rearrangement of R Co-activator BS is BLOCKED.
Mostrar resumen completo Ocultar resumen completo

Similar

Operadores Python
Giovanni Sanhuez
RAMAS DE LA MEDICINA
angelik.laverde9
Reported Speech
María Escobar
La Dictadura Franquista Selectividad
Diego Santos
Inglés - Verbos Compuestos I (Phrasal Verbs)
Sil Vere
Organizador Gráfico
r2p2casa
ESTRUCTURA DEL ESTADO COLOMBIANO
eduardo cuellar
LOS PRECIOS
Angela Guerrero
Mapa mental inteligencia emocional
Alexandra A
Estructura Titulo V. Revisión actos en vía administrativa, Ley 39/2015, de 1 de octubre de procedimiento administrativo común
Javier A